Arvinas Stock Forecast, Price & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARVN shares have decreased by 47.7% and is now trading at $23.03.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Arvinas.

Arvinas Inc (NASDAQ:ARVN) released its earnings results on Tuesday, August, 4th. The company reported ($0.65) EPS for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.06. The business had revenue of $5.75 million for the quarter, compared to analyst estimates of $5.73 million. Arvinas had a negative net margin of 182.59% and a negative return on equity of 31.68%.
View Arvinas' earnings history.

11 Wall Street analysts have issued 1-year price targets for Arvinas' stock. Their forecasts range from $38.00 to $75.00. On average, they expect Arvinas' stock price to reach $57.10 in the next year. This suggests a possible upside of 147.9% from the stock's current price.
View analysts' price targets for Arvinas.

Arvinas saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 5,450,000 shares, an increase of 62.2% from the August 31st total of 3,360,000 shares. Based on an average daily trading volume, of 401,400 shares, the days-to-cover ratio is currently 13.6 days. Currently, 20.8% of the shares of the stock are sold short.
View Arvinas' Short Interest.

Some companies that are related to Arvinas include FibroGen (FGEN), Biohaven Pharmaceutical (BHVN), Turning Point Therapeutics (TPTX), ChemoCentryx (CCXI), Amicus Therapeutics (FOLD), HYPERA S A/S (HYPMY), Insmed (INSM), Global Blood Therapeutics (GBT), Principia Biopharma (PRNB), SAGE Therapeutics (SAGE), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX) and GW Pharmaceuticals PLC- (GWPH).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Opko Health (OPK), Pfizer (PFE), Crispr Therapeutics (CRSP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Enphase Energy (ENPH) and Fortress Biotech (FBIO).

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (9.75%), Bellevue Group AG (4.03%), Gilder Gagnon Howe & Co. LLC (3.66%), Vanguard Group Inc. (2.80%), Avidity Partners Management LP (2.74%) and Deerfield Management Company L.P. Series C (2.57%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Hillhouse Capital Advisors LTD., Deerfield Management Company L.P. Series C, RTW Investments LP, Federated Hermes Inc., Gilder Gagnon Howe & Co. LLC, Holocene Advisors LP, and ArrowMark Colorado Holdings LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas.

ARVN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Avidity Partners Management LP, Bellevue Group AG, Two Sigma Advisers LP, Vanguard Group Inc., Man Group plc, Alyeska Investment Group L.P., and Candriam Luxembourg S.C.A.. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Briggs Morrison, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $23.03.

Arvinas has a market capitalization of $903.65 million and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 83 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]